Fisher Asset Management LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 1,334.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,376 shares of the medical research company’s stock after purchasing an additional 13,374 shares during the period. Fisher Asset Management LLC’s holdings in Charles River Laboratories International were worth $4,241,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its stake in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Bank of America Corp DE lifted its position in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after buying an additional 54,500 shares during the period. Amundi lifted its position in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after buying an additional 492,301 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Charles River Laboratories International by 457.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company’s stock worth $128,641,000 after buying an additional 357,817 shares during the period. Finally, Van Berkom & Associates Inc. boosted its stake in Charles River Laboratories International by 11.2% in the 1st quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after buying an additional 50,462 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, Director James C. Foster sold 24,042 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $11,058,600. This trade represents a 43.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 62,779 shares of company stock valued at $20,127,838 over the last ninety days. Insiders own 1.30% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have issued reports on CRL. Zacks Research lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $180.00 to $310.00 in a report on Thursday, August 6th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research note on Monday, July 20th. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Finally, Jefferies Financial Group increased their target price on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $311.67.
Read Our Latest Stock Analysis on CRL
Charles River Laboratories International Stock Performance
NYSE CRL opened at $335.29 on Tuesday. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $379.63. The company has a 50 day moving average of $312.13 and a 200-day moving average of $228.83. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. The firm has a market cap of $16.07 billion, a price-to-earnings ratio of 368.45, a PEG ratio of 3.08 and a beta of 1.36.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.97 by $0.12. The business had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. Charles River Laboratories International’s revenue was down 2.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.43 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Read More
- Five stocks we like better than Charles River Laboratories International
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
